Open AccessCandida auris: An Overview of the Emerging Drug-Resistant Fungal Infection
Author(s) -
Adekunle Sanyaolu,
Chuku Okorie,
Aleksandra Marinkovic,
Abdus Sattar Abbasi,
Stephanie Prakash,
Jasmine Mangat,
Zaheeda Hosein,
Nafees Haider,
Jennifer Chan
Publication year - 2022
Publication title -
infection and chemotherapy/gam'yeom gwa hwahag yo'beob/infection and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 26
eISSN - 2092-6448
pISSN - 1598-8112
DOI - 10.3947/ic.2022.0008
Subject(s) - candida auris , medicine , intensive care medicine , infection control , antifungal , drug resistance , antifungal drug , antifungal drugs , microbiology and biotechnology , dermatology , biology
Candida auris is an invasive fungal pathogen that has been recognized globally as a serious health threat due to its extensive innate and acquired resistance to antifungal drugs. A growing number of emerging cases of C. auris have been reported with resistance to the standard antifungal treatments including azoles, echinocandins, and polyenes, making it difficult to treat. Unlike other Candida species, C. auris is challenging to diagnose using the standard laboratory methods and are typically prone to misidentification, resulting in inappropriate management. Consequently, C. auris infections have spread globally. The Centers for Disease Control and Prevention data showed that clinical cases of C. auris increased from 329 in 2018 to 1,012 in 2021. The incidence and prevalence of this invasive fungal infection are high in immunocompromised and hospitalized patients. Patients who had an organ transplant, are on immunosuppressive agents, are diabetic, recent antibiotic use, catheter use, and prolonged hospital or nursing homestays are vulnerable to C. auris infections. C. auris is rapidly spreading across healthcare settings globally and monitoring of its virulence as well as devising appropriate treatment approaches are thus highly required.